Hyderabad: When the World Health Organization (WHO) is Dithering on the provision of Emergency Use (EUL) to Bharat Biotech’s Covaxin, the Center for Control and Prevention of the United States (CDC) has given permission to individuals who are vaccinated by Covaxin for US traveling, though with driver.
The CDC has placed Covaxin on the list of Covid-19 vaccine candidates who meet the requirements that meet the criteria for the exception below the category of participants in certain Covid-19 vaccine tests on Tuesday, according to the CDC website.
However, it is not clear whether this only applies to those who participate in the Covaxin phase-3 trial or even those who receive vaccines after Covaxin is given by EUA limited under the clinical test mode by Indian drug regulators in January this year even as a phase-3 trial ongoing.
Covaxin was removed from clinical test mode and provided regular EUA in March this year after the government raised the condition of the clinical test mode.
The other vaccine (not approved by the WHO or US government) which has made a list of exceptions including Chinese players Cansinobio AD5-NCOV and Clover biopharmaceuticals’ SCB-2019, Novavax and Serum NVX-COV2373 Institute or Covovax.
The CDC’s decision came on the day when who was delayed his decision to give EUL to Covaxin until November 3, after the technical advisory group (tag) met in Geneva on Tuesday.
The CDC’s decision came as a good news for those who had taken the first covid-19 vaccine dose that first developed as part of the clinical trial and had anxiously waiting for Nul Mid to be able to travel to the US without having to undergo quarantine.
“Airlines and airline operators must confirm that each of the closed individuals’ claims this exception has an official documentation (eg clinical testing, participant card, or modified vaccination cards) from clinical trial participation,” Web site CDC website.
The first criterion set to utilize this exception is that “passengers have participated or participated in the Covid-19 phase-3 vaccine test with a list of qualified vacurical candidates …
which meets the CDC criteria for exceptions.” The second criterion is that “passengers receive a complete range of Covid-19 qualifying vaccine candidates who are active (non-placebo) or EUL vaccines and include vaccine product names and the date received.” In accordance with CDC operators, airlines and airlines need to review the information served by passengers to ensure that passengers have completed the vaccination series at least 14 days before flight departure.